Upstream Processing

July 01, 2020

Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.

June 01, 2020

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.

May 01, 2020

Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.

April 03, 2020

New bioreactor designs, coupled with better media, process intensification and analytics, continue to improve upstream bioprocessing.

March 09, 2020

The new BIOSTAT STR Generation 3 with BIOBRAIN bioproduction platform offers process intensification with automated feed and bleed and integrated cell retention functionality.

March 02, 2020

Better understanding and control of cell behavior is yielding benefits, upstream and beyond.

March 02, 2020

The future of raw material sourcing for mAb production may lay in the sustainability of the source and the added benefits of newer technologies.

February 05, 2020

By establishing effective management of data and knowledge, it will be possible to employ advances, such as artificial intelligence and synthetic biology, to their full potential in upstream bioprocessing.

February 01, 2020

The production of viral vectors for use in gene therapy benefits from being able to use similar cell-culture processes as mAbs, but it faces limitations under current cell-culture technologies.

January 15, 2020

Horizon Discovery Group and Mammoth Biosciences have signed a collaboration and license agreement aimed at the development of the next generation of engineered Chinese hamster ovary (CHO) cell lines to improve biotherapeutics production.